Holen Sie sich die Stockscreener-App
3.04
7.60%
-0.25
Handel nachbörslich:
3.04
Schlusskurs vom Vortag:
$3.29
Offen:
$3.29
24-Stunden-Volumen:
59,127
Relative Volume:
1.43
Marktkapitalisierung:
$200.46M
Einnahmen:
$64.49M
Nettoeinkommen (Verlust:
$-71.40M
KGV:
-2.789
EPS:
-1.09
Netto-Cashflow:
$-52.00M
1W Leistung:
-4.10%
1M Leistung:
+4.29%
6M Leistung:
-4.70%
1J Leistung:
-33.77%
1-Tages-Spanne:
$3.04
$3.4039
1-Wochen-Bereich:
$2.99
$3.4039
52-Wochen-Spanne:
$2.58
$4.92
Sophia Genetics Sa Stock (SOPH) Company Profile
Firmenname
Sophia Genetics Sa
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie SOPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SOPH
Sophia Genetics Sa
|
3.04 | 200.46M | 64.49M | -71.40M | -52.00M | -1.09 |
|
VEEV
Veeva Systems Inc
|
282.61 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
59.18 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
59.31 | 10.79B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
101.28 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
38.67 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Sophia Genetics Sa Stock (SOPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | Guggenheim | Buy |
| 2023-11-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-03 | Eingeleitet | BTIG Research | Buy |
| 2022-11-23 | Eingeleitet | Credit Suisse | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-17 | Eingeleitet | Cowen | Outperform |
| 2021-08-17 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-17 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Sophia Genetics Sa Aktie (SOPH) Neueste Nachrichten
SOPHiA GENETICS Announces Key Approvals at 2025 Annual General Meeting - TipRanks
Precision Medicine Software Market Future Trends and Scope - openPR.com
Radiomics Market Key Players AnalysisRadiomics.io - openPR.com
SOPHiA GENETICS SA (NASDAQ:SOPH) Shares Sold by Squarepoint Ops LLC - Defense World
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today? - sharewise
Millennium Management LLC Increases Position in SOPHiA GENETICS SA (NASDAQ:SOPH) - Defense World
Dimensional Fund Advisors LP Has $68,000 Stock Holdings in SOPHiA GENETICS SA (NASDAQ:SOPH) - Defense World
Top Market Trend Impacting AI In Bioinformatics Development in the Coming Years: Bionl.AI Platform Revoluti... - WhaTech
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order? - Yahoo Finance
SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2025 Earnings Call Transcript - Insider Monkey
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates - MSN
SOPHiA GENETICS Q1 2025 Earnings Call Highlights - TipRanks
SOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
SOPHiA GENETICS SA 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SOPH) - Seeking Alpha
SOPHiA GENETICS sets date for annual shareholder meeting - Investing.com Australia
SOPHiA GENETICS sets date for annual shareholder meeting By Investing.com - Investing.com South Africa
Sophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ... By GuruFocus - Investing.com Canada
SOPHiA GENETICS Reports Strong Q1 2025 Growth - TipRanks
SOPHiA GENETICS Q1 2025 Earnings Call Transcript - MarketBeat
SOPHiA GENETICS Reports Q1 2025 Financial Results - TipRanks
SOPH Hits Revenue and Margin Milestones in Q1 2024 | SOPH Stock News - GuruFocus
SOPHiA GENETICS Reports First Quarter 2025 Results - Quantisnow
Earnings To Watch: Sophia Genetics SA (SOPH) Reports Q1 2025 Result - Yahoo Finance
Sophia Genetics SA expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Promising Penny Stocks To Consider In April 2025 - simplywall.st
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? - The Globe and Mail
SOPHia Genetics expands testing partnership with AstraZeneca - MSN
SOPHiA Genetics (SOPH) Expands Liquid Biopsy Collaboration with AstraZeneca - GuruFocus
SOPHiA GENETICS Expands Global Collaboration With AstraZeneca To Advance Liquid Biopsy Testing - Nasdaq
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR – Company AnnouncementFT.com - Financial Times
SOPHiA GENETICS SA's (NASDAQ:SOPH) market cap touched US$204m last week, benefiting both individual investors who own 51% as well as institutions - simplywall.st
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS - Yahoo Finance
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025 - marketscreener.com
SOPHiA GENETICS Q1 2025 Earnings: AI Healthcare Leader Reports Financial Results May 6 - Stock Titan
SOPHiA GENETICS (SOPH) Forecasts Revenue Growth Despite Volatili - GuruFocus
SOPHiA GENETICS (SOPH) Forecasts Revenue Growth Despite Volatility - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM Platform and its Liquid Biopsy Capabilities - MarketScreener
SOPHiA GENETICS Partners With Precision for Medicine - marketscreener.com
Major AI Breakthrough: SOPHiA GENETICS Partners to Transform Clinical Trial Analysis - Stock Titan
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities - MarketScreener
Precision Medicine Software Market: Global Expansion & Growth - openPR.com
AI In Genomics Market 2030: The $1 Billion Race Between IBM, NVIDIA & Illumina - blog.libero.it
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? - Yahoo Finance
Mesoblast (NASDAQ:MESO) & SOPHiA GENETICS (NASDAQ:SOPH) Financial Review - Defense World
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
With A 25% Price Drop For SOPHiA GENETICS SA (NASDAQ:SOPH) You'll Still Get What You Pay For - Simply Wall St
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC - Barchart
Tempus AI Surges 40% YTD: Are New Strategic Deals A Buy Signal? - Barchart.com
Two Use Cases for AI in Healthcare - Streetwise Reports
Finanzdaten der Sophia Genetics Sa-Aktie (SOPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.70%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):